Brainsway (BWAY) Stock Price, News & Analysis

Company Overview

BrainsWay Ltd. (NASDAQ: BWAY) is a medical technology company that develops and commercializes noninvasive therapies for brain disorders. Its core technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses a helmet-like device to deliver magnetic stimulation to targeted areas of the brain.

The company’s Deep TMS systems are used in the treatment of major depressive disorder and obsessive-compulsive disorder, and have also received regulatory clearances for certain additional indications, including smoking cessation. BrainsWay sells its systems to hospitals, clinics, and other healthcare providers, while also supporting treatment delivery through software, accessories, and related services.

BrainsWay was founded in Israel and serves healthcare markets in the United States and internationally. Its products have received regulatory authorizations in multiple jurisdictions, including U.S. Food and Drug Administration clearances for specified uses. The company is headquartered in Burlington, Massachusetts, and maintains operations connected with its global commercial and research activities.

Key Stats

• Today's Range: $11.16 to $11.58
• 50-Day Range: $11.21 to $14.74
• 52-Week Range: $7.14 to $17.40
• Volume: 123,871 shs
• Average Volume: 104,438 shs
• Market Capitalization: $457.24 million
• P/E Ratio: 25.82
• Dividend Yield: N/A
• Price Target: $18.20
• Consensus Rating: Moderate Buy

Brainsway Stock Analysis - MarketRank™

Brainsway scored higher than 95% of companies evaluated by MarketBeat, and ranked 13th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Brainsway has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Brainsway has a consensus price target of $18.20, representing about 60.2% upside from its current price of $11.36.

Amount of Analyst Coverage

Brainsway has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 72.73%

Earnings Growth

Earnings for Brainsway are expected to grow by 72.73% in the coming year, from $0.33 to $0.57 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Brainsway is 25.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Brainsway is 25.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.76.

Price to Book Value per Share Ratio

Brainsway has a P/B Ratio of 6.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.69% of the float of Brainsway has been sold short.

Short Interest Ratio / Days to Cover

Brainsway has a short interest ratio ("days to cover") of 1.73, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainsway has recently decreased by 9.76%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Brainsway does not currently pay a dividend.

Dividend Growth

Brainsway does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.36

News Sentiment

Brainsway has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Brainsway this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for BWAY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Brainsway to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Brainsway insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.00% of the stock of Brainsway is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

30.11% of the stock of Brainsway is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 11/01/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BWAY
• CIK: 1505065
• Web: www.brainsway.com
• Phone: (722) 582-4030
• Fax: N/A
• Employees: 129
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Brainsway: $18.20
• High Price Target: $20.00
• Low Price Target: $15.00
• Potential Upside/Downside: +60.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.44
• Trailing P/E Ratio: 25.82
• Forward P/E Ratio: 34.42
• P/E Growth: N/A
• Net Income: $7.57 million
• Net Margins: 15.65%
• Pretax Margin: 15.94%
• Return on Equity: 12.74%
• Return on Assets: 8.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.59
• Quick Ratio: 3.27

Sales & Book Value

• Annual Sales: $52.22 million
• Price / Sales: 8.76
• Cash Flow: $0.23 per share
• Price / Cash Flow: 48.52
• Book Value: $1.87 per share
• Price / Book: 6.07

Miscellaneous

• Outstanding Shares: 40,250,000
• Free Float: 32,605,000
• Market Cap: $457.24 million
• Optionable: Optionable
• Beta: 1.29